Legend Biotech (LEGN)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Oncologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 22/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 9.93% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy
- Legend Biotech (LEGN) Tests Its Valuation After Fresh CARVYKTI Five Year Data
- Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says
- Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma
- Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion
- LEGN’s New CEO From Novartis Paves Way For Buyout Speculation
- Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
- Legend Naming Novartis Executive as CEO
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Self-Oxygenating Microneedle Patches Enabled by Black Phosphorus Nanocomposites for Sequential Photothermal/Photodynamic Melanoma Therapy. — ACS Appl Mater Interfaces 2026 Sep 23 PMID 42771792
- Engineering a self-protecting dermal filler: active hyaluronidase inhibition extends the in vivo persistence of cross-linked hyaluronic acid hydrogels. — RSC Adv 2026 Sep 18 PMID 42761992
- Hyaluronidase-enhanced delivery in gene therapy and regenerative medicine for improved vector, cell, and cargo access. — Front Drug Deliv 2026 PMID 42756066
- Study on 3D-printed methacrylated hyaluronic acid/methacrylated carboxymethyl chitosan/curcumin composite scaffolds for jaw bone regeneration. — BMC Oral Health 2026 Sep 9 PMID 42754872
- Injectable Thermosensitive Hydrogel Incorporating Platelet-Derived Factors for Endometrial Repair. — Acta Biomater 2026 Sep 16 PMID 42749205
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Legend Biotech.
Full LEGN Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.